

Not Too Large and Not Too Small—Just the Right Size: A Hippo-Sized Heart

Edward E. Morrisey

Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size

Heallen et al

Science. 2011;332:458–461.

Hippo signaling is an important regulator of organ size by balancing both cell proliferation and apoptosis. In cardiac development, Wnt signaling has been shown to be an important mediator of early cardiomyocyte proliferation and differentiation. Recent studies have now shown that the Hippo pathway negatively regulates heart size through recruitment of the coactivator Yap to the Wnt transcriptional effector β -catenin to balance the level of cardiomyocyte proliferation.¹

How organs obtain the correct size during development is one of the least understood processes during development. The coordination of the proper level of cell proliferation as well as differentiation and maturation is regulated by multiple developmental pathways, but few have been specifically implicated in controlling organ size. Heart function is quite sensitive to the effects of cardiac organ size, especially during development. A heart that is too small can lead to cardiac insufficiency and developmental demise. In contrast, in the adult, pathological cardiac hypertrophy, which can cause an enlarged heart, can result in decreased cardiac function and severe heart disease. Thus, during development, regulation of cardiac size can have an important impact on cardiovascular function.

The Hippo pathway was originally shown to regulate organ size in *Drosophila* imaginal disc development.^{2,3} In vertebrates, the function of the Hippo pathway is less understood, but several orthologues of the *Drosophila* Hippo genes Mst1 and Mst2, which are serine/threonine kinases, have been identified as well as other components in the pathway. In a recent report, Heallen et al demonstrate that inactivation of one of these core components, the scaffolding protein Salvador, which interacts with Mst1/2 to form an active kinase




Figure. The Hippo pathway component Salvador (Salv) interacts with the Mst1/2 homologues of the Hippo protein, and this complex regulates phosphorylation of the Lats tumor suppressor gene. Lats in turn regulates phosphorylation of YAP. Phosphorylated YAP is excluded from the nucleus. Nonphosphorylated YAP interacts with both TEAD transcription factors and β -catenin, providing an important connection between the Hippo and Wnt/ β -catenin pathways that controls cardiomyocyte number and proliferation.

complex required for Hippo pathway function, leads to a dramatic form of cardiomegaly.¹ The authors show that the increase in heart size was accompanied by an increase in cardiomyocyte mitosis but not by an increase in Isl1+ cardiac progenitor proliferation. The authors went on to uncover an interesting mechanism for Hippo function by showing that the Yap coactivator, which is a transcriptional effector of Hippo signaling, complexes with β -catenin to promote Wnt signaling in developing cardiomyocytes. This coactivation of Wnt/ β -catenin signaling leads to the increased expression of a number of interesting target genes including Sox2, survivin/Birc5, and Snail2. Loss of β -catenin in the developing heart leads to decreased expression of these genes, supporting the finding that they are regulated by both Hippo and Wnt/ β -catenin signaling. Given the importance of Wnt/ β -catenin signaling in promoting cardiomyocyte proliferation and differentiation, these findings present a novel input that helps control cardiomyocyte proliferation to regulate overall heart size during development.

Much of what is known about Wnt/ β -catenin signaling in early cardiac development suggests a primary role in regulating proliferation and differentiation in second heart field progenitors.^{4–8} However, Heallen et al did not observe any difference in the proliferation rates between second heart field-derived and first heart field-derived structures, for example, right and left ventricular myocardium, respectively. This finding is somewhat unexpected and may suggest that the Hippo pathway interacts with the Wnt/ β -catenin pathway in both areas of the heart, but its role in first heart field is different than in the second heart field. One possibility is that components of the Hippo pathway may not be expressed in the second heart field and thus do not effect Wnt signaling. Alternatively, our understanding of Wnt/ β -catenin function in

The opinions expressed in this Commentary are not necessarily those of the editors or of the American Heart Association.

Commentaries serve as a forum in which experts highlight and discuss articles (published elsewhere) that the editors of *Circulation Research* feel are of particular significance to cardiovascular medicine.

Commentaries are edited by Aruni Bhatnagar and Ali J. Marian.

From the Department of Medicine, Department of Cell and Developmental Biology, Institute for Regenerative Medicine, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA.

Correspondence to Edward E. Morrisey, Department of Medicine, University of Pennsylvania, 956 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104. E-mail emorris@mail.med.upenn.edu

(*Circ Res*. 2011;109:614–615.)

© 2011 American Heart Association, Inc.

Circulation Research is available at <http://circres.ahajournals.org>
DOI: 10.1161/RES.0b013e3182303adf

the first heart field is incomplete and may be more complex than previously described.

One of the conundrums of Wnt/ β -catenin signaling in cardiac development has been the observation that several Wnt ligands are expressed in the myocardium much later and more broadly than Wnt/ β -catenin signaling has been observed using several methods including LEF/TCF transgenic reporters.^{4,7,9-11} Moreover, current concepts in cardiomyocyte differentiation from pluripotent stem cells suggest a biphasic role for Wnt signaling with the pathway having a procardiogenic role in development of precardiac mesoderm and an anticardiogenic role later during cardiomyocyte differentiation.^{12,13} One interpretation of these data is that Wnt/ β -catenin signaling may have little effect on cardiomyocyte proliferation after early progenitor expansion. However, this may be too simplistic. It is clear in other developmental systems that different Wnt ligands have different effects on Wnt/ β -catenin signaling. Noncanonical Wnt pathways that could act independent of β -catenin signaling may play a key role in balancing cardiomyocyte proliferation and differentiation. Noncanonical Wnt signaling can also inhibit canonical β -catenin dependent signaling, leading to a precise level of overall Wnt activity in cells and tissues that express multiple Wnt ligands. The findings by Heallen et al suggest an additional input for Wnt/ β -catenin signaling by the Hippo pathway, thus providing another level of control to maintain cardiomyocyte proliferation and ultimately heart size.

How Yap/ β -catenin interactions balance out the canonical LEF-TCF/ β -catenin interactions and whether these interactions are mutually exclusive or can occur simultaneously are points that still need to be more fully characterized. Only nonphosphorylated Yap interacts with β -catenin in this situation and activation of Hippo signaling phosphorylates Yap, leading to nuclear exclusion and inactivation of Yap/ β -catenin transcriptional activity. It is conceivable that the interaction between Yap/ β -catenin and either TEAD or LEF-TCF factors plays a crucial role in regulating the precise and gradual exit of the cell cycle noted in cardiomyocytes. This may be similar to how β -catenin interacts with some members of the Sox transcription factor family, resulting in inhibition of Wnt/ β -catenin signaling.^{14,15} Thus, differing inputs into the Wnt/ β -catenin signaling pathway may play crucial roles in regulating cardiomyocyte growth during later stages of cardiac development.

Although the full affects of Hippo signaling on cardiac organ size remain to be explored, the present study by Heallen et al strongly implicates that this pathway intersects with Wnt signaling to control cardiac size during development. These studies also outline potentially new targets for therapeutic approaches to modulate cardiomyocyte proliferation. The Mst1/2 kinases may provide attractive new targets for therapeutic inhibition to promote cardiomyocyte proliferation in the setting of injury. Inhibition of Gsk-3 β , which

regulates Wnt/ β -catenin signaling, has been shown to promote cardiomyocyte proliferation during development and in postnatal cardiomyocytes.¹⁶ Whether activation of Wnt or inactivation of Hippo signaling will promote cardiomyocyte proliferation in the setting of cardiac injury is still unknown. However, the current findings are sure to spur interest in looking more closely into these pathways in the adult heart.

References

1. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysiak E, Johnson RL, Martin JF. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science*. 2011;332:458–461.
2. Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, Zider A. Scalloped interacts with Yorkie, the nuclear effector of the hippo tumor-suppressor pathway in drosophila. *Curr Biol*. 2008;18:435–441.
3. Hariharan IK, Bilder D. Regulation of imaginal disc growth by tumor-suppressor genes in drosophila. *Annu Rev Genet*. 2006;40:335–361.
4. Cohen ED, Wang Z, Lepore JJ, Lu MM, Taketo MM, Epstein DJ, Morrisey EE. Wnt/beta-catenin signaling promotes expansion of isl-1-positive cardiac progenitor cells through regulation of fgf signaling. *J Clin Invest*. 2007;117:1794–1804.
5. Klaus A, Saga Y, Taketo MM, Tzahor E, Birchmeier W. Distinct roles of wnt/beta-catenin and bmp signaling during early cardiogenesis. *Proc Natl Acad Sci U S A*. 2007;104:18531–18536.
6. Kwon C, Arnold J, Hsiao EC, Taketo MM, Conklin BR, Srivastava D. Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. *Proc Natl Acad Sci U S A*. 2007;104:10894–10899.
7. Lin L, Cui L, Zhou W, Duford D, Zhang X, Cai CL, Bu L, Yang L, Martin J, Kemler R, Rosenfeld MG, Chen J, Evans SM. Beta-catenin directly regulates islet1 expression in cardiovascular progenitors and is required for multiple aspects of cardiogenesis. *Proc Natl Acad Sci U S A*. 2007;104:9313–9318.
8. Qiang Y, Martin-Puig S, Chiravuri M, Chen S, Xu H, Bu L, Jiang X, Lin L, Granger A, Moretti A, Caron L, Wu X, Clarke J, Taketo MM, Laugwitz KL, Moon RT, Gruber P, Evans SM, Ding S, Chien KR. The renewal and differentiation of isl1+ cardiovascular progenitors are controlled by a wnt/beta-catenin pathway. *Cell Stem Cell*. 2007;1:165–179.
9. Jaspard B, Couffignal T, Dufourcq P, Moreau C, Duplaa C. Expression pattern of mouse sfrp-1 and mwnt-8 gene during heart morphogenesis. *Mech Dev*. 2000;90:263–267.
10. Schleiffarth JR, Person AD, Martinsen BJ, Sukovich DJ, Neumann A, Baker CV, Lohr JL, Cornfield DN, Ekker SC, Petryk A. Wnt5a is required for cardiac outflow tract septation in mice. *Pediatr Res*. 2007;61:386–391.
11. Tian Y, Yuan L, Goss AM, Wang T, Yang J, Lepore JJ, Zhou D, Schwartz RJ, Patel V, Cohen ED, Morrisey EE. Characterization and in vivo pharmacological rescue of a Wnt2-gata6 pathway required for cardiac inflow tract development. *Dev Cell*. 2010;18:275–287.
12. Ueno S, Weidinger G, Osugi T, Kohn AD, Golob JL, Pabon L, Reinecke H, Moon RT, Murry CE. Biphasic role for wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. *Proc Natl Acad Sci U S A*. 2007;104:9685–9690.
13. Paige SL, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry CE. Endogenous wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. *PLoS One*. 2010;5:e11134.
14. Zhang Y, Li S, Yuan L, Tian Y, Weidenfeld J, Yang J, Liu F, Chokas AL, Morrisey EE. Foxp1 coordinates cardiomyocyte proliferation through both cell-autonomous and nonautonomous mechanisms. *Genes Dev*. 2010;24:1746–1757.
15. Zorn AM, Barish GD, Williams BO, Lavender P, Klymkowsky MW, Varmus HE. Regulation of wnt signaling by sox proteins: Xsox17 alpha/beta and xsox3 physically interact with beta-catenin. *Mol Cell*. 1999;4:487–498.
16. Tseng AS, Engel FB, Keating MT. The gsk-3 inhibitor bio promotes proliferation in mammalian cardiomyocytes. *Chem Biol*. 2006;13:957–963

Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Not Too Large and Not Too Small—Just the Right Size: A Hippo-Sized Heart Edward E. Morrisey

Circ Res. 2011;109:614-615

doi: 10.1161/RES.0b013e3182303adf

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2011 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the
World Wide Web at:

<http://circres.ahajournals.org/content/109/6/614>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation Research* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation Research* is online at:
<http://circres.ahajournals.org/subscriptions/>